

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



CHINA ISOTOPE & RADIATION CORPORATION

中國同輻股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 1763)

ANNOUNCEMENT PUBLISHED IN OTHER OVERSEAS REGULATORY MARKETS

This announcement is published pursuant to Rule 13.10B of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited.

References are made to the announcement dated 26 March 2024 and the circular dated 14 May 2024 of China Isotope & Radiation Corporation (the “**Company**”), in relation to, *inter alia*, the public issue of the corporate bonds to professional investors (the “**Issue of Bonds**”).

Reference is made to the “2024 First Quarterly Financial Statements of China Isotope & Radiation Corporation” published by the Company in relation to the application for the Issue of Bonds on the website of the Shanghai Stock Exchange (<http://www.sse.com.cn/>) on 26 June 2024, which is for reference purpose only.

By order of the Board
China Isotope & Radiation Corporation
Zhang Junqi
Chairman

Beijing, the PRC, 26 June 2024

As at the date of this announcement, the Board comprises Mr. Zhang Junqi, Mr. Wang Yao and Mr. Fan Guomin as executive Directors; Mr. Chen Zan, Mr. Ding Jianmin, Ms. Chang Jinyu and Ms. Liu Xiuhong as non-executive Directors; and Mr. Poon Chiu Kwok, Mr. Tian Jiahe, Ms. Chen Jingshan and Mr. Lu Chuang as independent non-executive Directors.

Consolidated Balance Sheet

31 March 2024

Prepared by China Isotope & Radiation Corporation

Unit: RMB

Item	Line No.	Closing balance	Opening balance
Current assets:	1		
Cash	2	2,727,296,593.66	2,891,624,494.82
△Settlement reserves	3		
△Placements with banks and other financial institutions	4		
Financial assets held for trading	5		
★Financial assets at fair value through profit or loss	6		
Derivative financial assets	7		
Bills receivable	8	67,393,181.66	96,231,228.36
Trade receivables	9	3,786,597,719.87	3,764,560,489.57
Financing receivables	10	21,144,343.73	15,549,457.06
Prepayments	11	476,729,581.21	337,908,078.00
▲Premium receivables	12		
▲Receivables from reinsurers	13		
▲Deposits receivable from reinsurance	14		
Centralized management of receivables	15		
Other receivables	16	135,161,278.59	130,617,941.22
Including: Dividend receivable	17	39,587,655.90	39,587,655.90
△Financial assets held under resale agreements	18		
Inventory	19	953,882,539.65	814,164,981.59
Including: Raw materials	20	249,740,568.36	239,393,863.74
Stock inventory (finished products)	21	594,335,203.59	464,086,561.40
Contract assets	22	16,509,715.24	19,862,085.74
△Insurance contract assets	23		
△Reinsurance contract assets	24		
Held-for-sale assets	25		
Non-current assets due within one year	26		
Other current assets	27	110,229,183.99	123,951,207.01
Total current assets	28	8,294,944,137.60	8,194,469,963.37
Non-current assets:	29		
△Loans and advances granted	30	—	—
Debt investment	31		
★Financial assets available for sale	32		
Other debt investment	33		
★Held-to-maturity investment	34		
Long-term receivables	35	49,195,876.37	49,195,876.37
Long-term equity investment	36	605,812,086.04	623,112,878.33
Other equity instrument investment	37	156,393,869.30	156,393,869.30
Other non-current financial assets	38		
Investment properties	39	44,546,287.94	46,052,893.04
Fixed assets	40	2,016,794,943.16	2,014,259,225.96
Including: Cost of fixed assets	41	3,103,643,208.07	3,055,173,399.84
Accumulated depreciation	42	1,078,604,882.32	1,032,652,443.41
Provision for fixed asset impairment	43	8,261,730.47	8,261,730.47
Construction in progress	44	1,018,733,447.35	961,357,711.95
Productive biological assets	45		
Oil and gas assets	46		
Right-to-use assets	47	52,914,523.68	58,810,847.46
Intangible assets	48	440,731,879.25	335,268,317.44
Development costs	49	122,675,147.72	89,995,859.28
Goodwill	50	81,525,585.48	81,525,585.48
Long-term deferred expenses	51	23,121,506.06	24,938,262.50
Deferred income tax assets	52	220,431,144.69	220,431,144.69
Other non-current assets	53	299,111,443.04	328,552,493.03
Including: Physical assets reserve specifically authorized	54		
Total non-current assets	55	5,131,987,740.08	4,989,894,964.83
	56		
	57		
	58		
	59		
	60		
	61		
	62		
	63		
	64		
	65		
	66		
	67		
	68		
	69		
	70		
	71		
	72		
	73		
	74		
	75		
	76		
Total assets	77	13,426,931,877.68	13,184,364,928.20

Person in charge of the Company:

Person in charge of accounting:

Head of the accounting department:

Consolidated Balance Sheet (Continued)

31 March 2024

Prepared by China Isotope & Radiation Corporation

Unit: RMB

Item	Line No.	Closing balance	Opening balance
Current liabilities:	78		
Short-term borrowings	79	226,582,465.27	190,891,654.85
△Borrowings from central bank	80		
△Placements from banks and other financial institutions	81		
Financial liabilities held for trading	82		
☆Financial liabilities at fair value through profit or loss	83		
Derivative financial liabilities	84		
Bills payable	85		
Trade payables	86	702,874,409.54	626,664,808.34
Advances received	87	8,926,402.28	401,063.36
Contract liabilities	88	439,917,924.18	443,382,597.20
△Amount from sales of repurchased financial assets	89		
△Absorbing deposit and interbank deposit	90		
△Acting trading securities	91		
△Acting underwriting securities	92		
△Premiums received in advance	93		
Staff remuneration payable	94	108,727,130.68	176,697,632.53
Including: Salary payable	95	94,251,322.12	162,121,608.70
Benefits payable	96		
#Including: Employee bonus and welfare fund	97		
Tax charge payable	98	96,762,476.03	151,250,390.95
Including: Tax payable	99	94,116,190.16	146,917,974.23
Other payables	100	2,573,302,071.82	2,580,993,809.00
Including: Dividend payable	101	19,402,375.27	19,402,375.27
▲Handling charge and commissions payable	102		
▲Payables to reinsurers	103		
Held-for-sale liabilities	104		
Non-current liabilities due within one year	105	53,558,075.69	45,292,845.68
Other current liabilities	106	30,213,981.44	38,343,087.83
Total current liabilities	107	4,240,864,936.93	4,253,917,889.74
Non-current liabilities:	108		
▲Provision for insurance contracts	109		
Long-term borrowings	110	1,545,404,817.42	1,447,011,352.72
Debentures payable	111		
Including: Preferred shares	112		
Perpetual bonds	113		
△Insurance contract liabilities	114		
△Reinsurance contract liabilities	115		
Lease liabilities	116	33,490,549.78	31,322,113.08
Long-term payables	117	66,662,838.49	67,737,819.44
Long-term employee remuneration payable	118	44,006,620.00	44,006,620.00
Accrued liabilities	119	140,768,033.67	139,728,351.50
Deferred income	120	52,243,773.17	52,434,591.17
Deferred income tax liabilities	121	8,708,158.05	8,876,021.82
Other non-current liabilities	122		
Including: Special reserve fund	123		
Total non-current liabilities	124	1,891,284,790.58	1,791,116,869.73
Total liabilities	125	6,132,149,727.51	6,045,034,759.47
Owners' equity:	126		
Paid-in capital	127	319,874,900.00	319,874,900.00
Government capital	128		
State-owned legal person's capital	129	239,906,100.00	239,906,100.00
Collective capital	130		
Private capital	131	79,968,800.00	79,968,800.00
Foreign capital	132		
#Less: Investment returned	133		
Net paid-in capital	134	319,874,900.00	319,874,900.00
Other equity instruments	135		
Including: Preference shares	136		
Perpetual bonds	137		
Capital reserves	138	2,120,528,084.89	2,120,528,084.89
Less: Treasury stock	139		
Other comprehensive income	140	38,134,282.28	38,134,282.28
Including: Foreign currency translation differences	141		
Special reserve	142	61,425,816.85	58,776,539.36
Surplus reserves	143	160,402,577.50	160,402,577.50
Including: Statutory reserves	144	160,402,577.50	160,402,577.50
Discretionary reserve	145		
#Reserve funds	146		
#Enterprise development fund	147		
#Profit return for investment	148		
△Provision for general risk	149		
Unallocated profits	150	2,074,658,394.53	1,995,605,690.67
Total equity attributable to the parent's owners	151	4,775,024,056.05	4,693,322,074.70
*Minority interests	152	2,519,758,094.12	2,446,008,094.03
Total owners' equity	153	7,294,782,150.17	7,139,330,168.73
Total liabilities and owners' equity	154	13,426,931,877.68	13,184,364,928.20

Person in charge of the Company:

Person in charge of accounting:

Head of the accounting department:

Balance Sheet of the Parent Company

31 March 2024

Prepared by China Isotope & Radiation Corporation

Unit: RMB

Item	Line No.	Closing balance	Opening balance
Current assets:	1		
Cash	2	471,149,522.78	436,485,960.79
Financial assets held for trading	3		
★Financial assets at fair value through profit or loss	4		
Derivative financial assets	5		
Bills receivable	6		1,831,420.68
Trade receivables	7	386,715,843.46	421,656,042.79
Financing receivables	8	11,132,097.64	10,958,600.00
Prepayments	9	189,047,367.21	128,372,958.22
Centralized management of receivables	10		
Other receivables	11	148,431,377.19	171,521,499.46
Including: Dividend receivable	12	136,540,202.91	136,540,202.91
Inventory	13	170,467,240.65	161,238,493.54
Including: Raw materials	14		
Stock inventory (finished products)	15	164,036,596.98	147,242,223.04
Contract assets	16		
Held-for-sale assets	17		
Non-current assets due within one year	18		
Other current assets	19	266,474,566.42	283,130,025.18
Total current assets	20	1,643,418,015.35	1,615,195,000.66
Non-current assets:	21		
Debt investment	22		
★Financial assets available for sale	23		
Other debt investment	24		
★Held-to-maturity investment	25		
Long-term receivables	26		
Long-term equity investment	27	2,367,975,837.40	2,384,379,130.31
Other equity instrument investment	28	156,282,399.54	156,282,399.54
Other non-current financial assets	29		
Investment properties	30	56,308.74	57,443.52
Fixed assets	31	19,294,695.36	20,159,903.84
Including: Cost of fixed assets	32	52,807,609.36	52,781,775.85
Accumulated depreciation	33	33,512,914.00	32,621,872.01
Provision for fixed asset impairment	34		
Construction in progress	35		
Productive biological assets	36		
Oil and gas assets	37		
Right-to-use assets	38	7,691,863.69	8,367,500.36
Intangible assets	39	10,774,425.32	11,662,241.99
Development costs	40		
Goodwill	41		
Long-term deferred expenses	42	990,825.69	1,080,900.75
Deferred income tax assets	43	9,972,528.85	9,972,528.85
Other non-current assets	44	7,238,679.23	7,238,679.23
Including: Physical assets reserve specifically authorized	45		
Total non-current assets	46	2,580,277,563.82	2,599,200,728.39
Total assets	47	4,223,695,579.17	4,214,395,729.05

Person in charge of the Company:

Person in charge of accounting:

Head of the accounting department:

Balance Sheet of the Parent Company (Continued)

31 March 2024

Prepared by China Isotope & Radiation Corporation

Unit: RMB

Item	Line No.	Closing balance	Opening balance
Current liabilities:	48		
Short-term borrowings	49		
Financial liabilities held for trading	50		
☆Financial liabilities at fair value through profit or loss	51		
Derivative financial liabilities	52		
Bills payable	53		
Trade payables	54	81,185,666.95	34,616,298.03
Advances received	55		
Contract liabilities	56	125,604,226.20	129,096,868.62
Staff remuneration payable	57	10,003,564.35	22,369,600.46
Including: Salary payable	58	6,753,887.08	18,902,798.18
Benefits payable	59		
#Including: Employee bonus and welfare fund	60		
Tax charge payable	61	221,415.98	6,051,820.65
Including: Tax payable	62	221,415.98	5,457,258.08
Other payables	63	89,461,019.69	102,958,925.99
Including: Dividend payable	64		
Held-for-sale liabilities	65		
Non-current liabilities due within one year	66	19,619,690.30	19,619,690.30
Other current liabilities	67	15,207,971.46	16,262,014.97
Total current liabilities	68	341,303,554.93	330,975,219.02
Non-current liabilities:	69		
Long-term borrowings	70	823,485,432.71	827,063,529.87
Debentures payable	71		
Including: Preferred shares	72		
Perpetual bonds	73		
Lease liabilities	74	5,490,492.47	6,172,474.38
Long-term payables	75	601,050.00	601,050.00
Long-term employee remuneration payable	76	25,969,000.00	25,969,000.00
Accrued liabilities	77		
Deferred income	78		
Deferred income tax liabilities	79		
Other non-current liabilities	80		
Including: Special reserve fund	81		
Total non-current liabilities	82	855,545,975.18	859,806,054.25
Total liabilities	83	1,196,849,530.11	1,190,781,273.27
Owners' equity:	84		
Paid-in capital	85	319,874,900.00	319,874,900.00
Government capital	86		
State-owned legal person's capital	87	239,906,100.00	239,906,100.00
Collective capital	88		
Private capital	89	79,968,800.00	79,968,800.00
Foreign capital	90		
#Less: Investment returned	91		
Net paid-in capital	92	319,874,900.00	319,874,900.00
Other equity instruments	93		
Including: Preference shares	94		
Perpetual bonds	95		
Capital reserves	96	2,237,221,975.55	2,237,221,975.55
Less: Treasury stock	97		
Other comprehensive income	98	42,385,721.46	42,385,721.46
Including: Foreign currency translation differences	99		
Special reserve	100	2,423,702.41	2,558,306.26
Surplus reserves	101	159,937,450.00	159,937,450.00
Including: Statutory reserves	102	159,937,450.00	159,937,450.00
Discretionary reserve	103		
#Reserve funds	104		
#Enterprise development fund	105		
#Profit return for investment	106		
Unallocated profits	107	265,002,299.64	261,636,102.51
Total owners' equity	108	3,026,846,049.06	3,023,614,455.78
Total liabilities and owners' equity	109	4,223,695,579.17	4,214,395,729.05

Person in charge of the Company:

Person in charge of accounting:

Head of the accounting department:

Consolidated Income Statement

March 2024

Prepared by China Isotope & Radiation Corporation

Unit: RMB

Item	Line No.	Amount for the year	Amount for the previous year
I. Total Operating Revenue	1	1,274,044,318.13	1,135,761,891.43
Including: Operating revenue	2	1,274,044,318.13	1,135,761,891.43
△Interest income	3		
△Insurance service income	4		
▲Premium earned	5		
△Handling fee and commission income	6		
II. Total Operating Cost	7	1,096,324,688.25	1,036,485,560.35
Including: Operating cost	8	582,408,869.13	521,257,072.67
△Interest expenses	9		
△Handling fee and commission expenses	10		
△Insurance service expenses	11		
△Allocation of reinsurance premiums paid	12		
△Less: Amounts recovered from reinsurance contracts	13		
△Insurance finance expenses from insurance contracts issued	14		
△Less: Finance income from reinsurance contracts held	15		
▲Surrender value	16		
▲Net cash in compensation	17		
▲Net provisions for insurance contract	18		
▲Policy payment expense	19		
▲Reinsurance expenses	20		
Taxes and surcharges	21	11,502,977.08	11,087,538.36
Sales expenses	22	320,320,049.19	332,107,734.29
Administration expenses	23	117,419,715.98	108,953,162.55
Research and development expenses	24	55,721,681.72	64,404,154.27
Financial expenses	25	8,951,395.15	-1,324,101.79
Including: Interest expenses	26	11,101,885.17	5,741,411.64
Interest income	27	5,730,206.38	4,545,775.38
Net exchange losses (Net exchange gains marked with "-")	28	3,089,378.49	-3,745,057.55
Others	29		
Add: Other income	30	3,021,506.32	15,843,941.87
Investment income (Loss marked with "-")	31	3,468,106.62	3,333,787.37
Including: Income from investment in associates and joint ventures	32	3,468,106.62	3,333,787.37
De-recognition of revenue of financial assets measured at amortized cost	33		
△Exchange gains (Losses marked with "-")	34		
Gains on net exposure hedges (Losses marked with "-")	35		
Gains from change in fair value (Losses marked with "-")	36		
Credit impairment loss (Losses marked with "-")	37	-55,575.68	77,771.26
Asset impairment losses (Losses marked with "-")	38		
Gains from disposal of assets (Losses marked with "-")	39		
III. Operating profit (Loss marked with "-")	40	184,153,667.14	118,531,831.58
Add: Non-operating income	41	1,057,383.97	706,810.83
Government Grants	42	854,280.87	30,376.79
Less: Non-operating expenses	43	173,068.49	375,791.68
IV. Total profit (Total loss marked with "-")	44	185,037,982.62	118,862,850.73
Less: Income tax expenses	45	35,090,178.44	23,984,511.81
V. Net profit (Net loss marked with "-")	46	149,947,804.18	94,878,338.92
(I) Items classified according to ownership	47		
Net profit attributable to the owners of parent company	48	79,052,703.86	32,180,536.11
*Minority interests	49	70,895,100.32	62,697,802.81
(II) Items classified by continuing operations	50		
Net profit from continuing operation	51	149,947,804.18	94,878,338.92
Net profit from discontinued operation	52		
VI. Net other comprehensive income after tax	53		
Net other comprehensive income after tax attributable to the owners of the parent company	54		
(I) Other comprehensive income that cannot be reclassified to profit or loss	55		
1. Changes arising from the remeasurement of defined benefit plans	56		
2. Other comprehensive income under equity method that cannot be reclassified into profit or loss	57		
3. Changes in fair value of investment in other equity instruments	58		
4. Changes in fair value of the Company's own credit risk	59		
△5. Changes in the financial component of insurance contracts that cannot be reclassified to profit or loss	60		
6. Others	61		
(II) Other comprehensive income that will be reclassified to profit or loss	62		
1. Other comprehensive income that can be reclassified into profit or loss under equity method	63		
2. Changes in fair value of other debt investments	64		
☆3. Gains and losses from changes in fair value of available-for-sale financial assets	65		
4. Amount of financial assets reclassified into other comprehensive income	66		
☆5. Gains and losses from held-to-maturity investment reclassified as available-for-sale financial assets	67		
6. Credit impairment provisions for other debt investment	68		
7. Reserves for cash flows hedges (effective part of hedging gains and losses from cash flows)	69		
8. Exchange differences from retranslation of financial statements	70		
△9. Changes in the financial component of insurance contracts that can be reclassified to profit or loss	71		
△10. Changes in the financial component of reinsurance contracts that can be reclassified to profit or loss	72		
11. Others	73		
*Net other comprehensive income after tax attributable to minority shareholders	74		
VII. Total comprehensive income	75	149,947,804.18	94,878,338.92
Total comprehensive income attributable to owners of the parent company	76	79,052,703.86	32,180,536.11
*Total comprehensive income attributable to minority shareholders	77	70,895,100.32	62,697,802.81
VIII. Earnings per share:	78		
(I) Basic earnings per share	79	0.25	0.10
(II) Diluted earnings per share	80	0.25	0.10

Person in charge of the Company: Person in charge of accounting: Head of the accounting department:

Income Statement of the Parent Company

March 2024

Prepared by China Isotope & Radiation Corporation

Unit: RMB

Item	Line No.	Amount for the year	Amount for the previous year
I. Operating Revenue	1	202,208,452.61	117,320,443.20
Less: Operating cost	2	159,322,649.10	88,904,872.68
Taxes and surcharges	3	44,788.54	35,069.16
Sales expenses	4	15,428,722.21	19,333,107.03
Administration expenses	5	26,015,943.25	19,452,888.90
Research and development expenses	6	4,157.09	
Financial expenses	7	5,570,213.34	1,897,868.42
Including: Interest expenses	8	5,775,945.83	4,001,413.60
Interest income	9	523,527.97	1,966,265.82
Net exchange losses (Net exchange gains marked with "-")	10	272,277.73	-114,748.07
Others	11		
Add: Other income	12		127,986.87
Investment income (Loss marked with "-")	13	6,724,346.62	3,969,000.00
Including: Income from investment in associates and joint ventures	14	4,365,606.00	3,969,000.00
De-recognition of revenue of financial assets measured at amortized cost	15		
Gains on net exposure hedges (Losses marked with "-")	16		
Gains from change in fair value (Losses marked with "-")	17		
Credit impairment loss (Losses marked with "-")	18		
Asset impairment losses (Losses marked with "-")	19		
Gains from disposal of assets (Losses marked with "-")	20		
II. Operating profit (Loss marked with "-")	21	2,546,325.70	-8,206,376.12
Add: Non-operating income	22	820,000.00	33,474.66
Government Grants	23	820,000.00	
Less: Non-operating expenses	24	128.57	
III. Total profit (Total loss marked with "-")	25	3,366,197.13	-8,172,901.46
Less: Income tax expenses	26		
IV. Net profit (Net loss marked with "-")	27	3,366,197.13	-8,172,901.46
(I) Net profit from continuing operation	28	3,366,197.13	-8,172,901.46
(II) Net profit from discontinued operation	29		
V. Net other comprehensive income after tax	30		
(I) Other comprehensive income that cannot be reclassified to profit or loss	31		
1. Changes arising from the remeasurement of defined benefit plans	32		
2. Other comprehensive income under equity method that cannot be reclassified into profit or loss	33		
3. Changes in fair value of investment in other equity instruments	34		
4. Changes in fair value of the Company's own credit risk	35		
5. Others	36		
(II) Other comprehensive income that will be reclassified to profit or loss	37		
1. Other comprehensive income that can be reclassified into profit or loss under equity method	38		
2. Changes in fair value of other debt investments	39		
☆3. Gains and losses from changes in fair value of available-for-sale financial assets	40		
4. Amount of financial assets reclassified into other comprehensive income	41		
☆5. Gains and losses from held-to-maturity investment reclassified as available-for-sale financial assets	42		
6. Credit impairment provisions for other debt investment	43		
7. Reserves for cash flows hedges (effective part of hedging gains and losses from cash flows)	44		
8. Exchange differences from retranslation of financial statements	45		
9. Others	46		
VI. Total comprehensive income	47	3,366,197.13	-8,172,901.46

Person in charge of the Company:

Person in charge of accounting:

Head of the accounting department:

Consolidated Statement of Cash Flows

March 2024

Prepared by China Isotope & Radiation Corporation

Unit: RMB

Item	Line No.	Amount for the year	Amount for the previous year
I. Cash flows generated from operating activities:	1		
Cash from sales of goods and provision of labour services	2	1,419,902,595.90	1,357,282,299.55
△Net increase in customer deposits and interbank deposits	3		
△Net increase in borrowings from central bank	4		
△Net increase in borrowings from other financial institutions	5		
△Cash received from premium of insurance contracts issued	6		
△Net cash received from reinsurance contracts	7		
▲Cash received from premium of original insurance contracts	8		
▲Net cash received from reinsurance business	9		
▲Net increase in deposit from insurance policy holders and investments	10		
△Net increase in disposal of financial assets at fair value through profit or loss	11		
△Cash received from interest, fee and commission	12		
△Net increase of placements from banks and other financial institutions	13		
△Net increase of repurchase business	14		
△Net cash received from acting trading securities	15		
Tax refunds received	16	18,696,556.19	7,243,042.32
Cash from other operating activities	17	30,124,757.00	75,259,754.39
Sub-total of cash inflows from operating activities	18	1,468,723,909.09	1,439,785,096.26
Cash paid for purchase of goods and engagement of labour services	19	946,566,474.97	1,168,864,703.13
△Net cash increase of customer loans and advances	20		
△Net increase of deposits in central banks and other banks	21		
△Cash paid for claims from insurance contracts issued	22		
△Net cash paid for reinsurance contracts	23		
△Net increase of insurance policy loans	24		
▲Cash paid for the compensation under the original insurance contract	25		
△Net increase of placements with banks and other financial institutions	26		
△Cash paid for interest, fee and commission	27		
▲Cash dividends paid for insurance policies	28		
Cash paid to and for employees	29	300,364,560.82	304,893,060.60
Tax payments	30	185,396,178.49	225,024,398.18
Cash paid for other operating activities	31	124,674,267.30	134,467,305.72
Sub-total of cash outflows from operating activities	32	1,557,001,481.58	1,833,249,467.63
Net cash flows generated from operating activities	33	-88,277,572.49	-393,464,371.37
II. Cash flows generated from investing activities:	34		
Cash received from disposal of investment	35	18,227,820.00	
Cash from investment gains	36	2,541,078.91	
Net cash received from disposal of fixed assets, intangible assets and other long-term assets	37		765.00
Net cash received from disposal of subsidiaries and other business units	38		
Cash received from other operating activities	39	262,437,749.40	1,402,992.96
Sub-total of cash inflows from investing activities	40	283,206,648.31	1,403,757.96
Cash paid for acquisition of fixed assets, intangible assets and other long-term assets	41	243,673,466.08	103,934,156.89
Cash paid for investments	42		
▲Net increase in secured loans	43		
Net cash paid for acquisition of subsidiaries and other business units	44		
Cash paid for other investing activities	45	70,000,000.00	210,083.14
Sub-total of cash outflows from investing activities	46	313,673,466.08	104,144,240.03
Net cash flows generated from investing activities	47	-30,466,817.77	-102,740,482.07
III. Cash flows generated from financing activities:	48		
Cash received from investments	49	1,495,000.00	15,600,000.00
*Including: Cash received by subsidiaries from investments by minority shareholders	50	1,495,000.00	15,600,000.00
Cash received from borrowings	51	168,103,730.80	25,883,000.00
Cash received from other financing activities	52		8,000,000.00
Sub-total of cash inflows from financing activities	53	169,598,730.80	49,483,000.00
Cash paid for repayment of debts	54	17,755,750.68	12,077,500.00
Cash paid for distribution of dividends, profits or payment of interests	55	16,117,367.65	7,325,273.94
*Including: Dividends and profits distributed to minority shareholders by subsidiaries	56		
Cash paid for other financing activities	57	3,322,513.01	4,887,455.70
Sub-total of cash outflows from financing activities	58	37,195,631.34	24,290,229.64
Net cash flows generated from financing activities	59	132,403,099.46	25,192,770.36
IV. Effects of changes in exchange rates on cash and cash equivalents	60	666.13	124,098.29
V. Net increase in cash and cash equivalents	61	13,659,375.33	-470,887,984.79
Add: Balance of cash and cash equivalents as at the beginning of the period	62	2,376,459,109.21	2,236,829,107.92
VI. Balance of cash and cash equivalents as at the end of the period	63	2,390,118,484.54	1,765,941,123.13

Person in charge of the Company:

Person in charge of accounting:

Head of the accounting department:

Statement of Cash Flows of the Parent Company

March 2024

Prepared by China Isotope & Radiation Corporation

Unit: RMB

Item	Line No.	Amount for the year	Amount for the previous year
I. Cash flows generated from operating activities:	1		
Cash from sales of goods and provision of labour services	2	259,811,425.76	114,163,980.69
Tax refunds received	3	18,604,340.01	7,174,317.36
Cash from other operating activities	4	15,122,204.05	5,824,067.11
Sub-total of cash inflows from operating activities	5	293,537,969.82	127,162,365.16
Cash paid for purchase of goods and engagement of labour services	6	212,179,251.17	176,258,790.15
Cash paid to and for employees	7	33,199,228.29	28,979,345.53
Tax payments	8	4,833,266.39	2,688,259.80
Cash paid for other operating activities	9	21,325,216.24	31,901,499.39
Sub-total of cash outflows from operating activities	10	271,536,962.09	239,827,894.87
Net cash flows generated from operating activities	11	22,001,007.73	-112,665,529.71
II. Cash flows generated from investing activities:	12		
Cash received from disposal of investment	13	18,227,820.00	
Cash from investment gains	14	2,541,078.91	
Net cash received from disposal of fixed assets, intangible assets and other long-term assets	15		
Net cash received from disposal of subsidiaries and other business units	16		
Cash received from other operating activities	17	1,996,027.49	15,053,200.00
Sub-total of cash inflows from investing activities	18	22,764,926.40	15,053,200.00
Cash paid for acquisition of fixed assets, intangible assets and other long-term assets	19	28,295.00	58,079.00
Cash paid for investments	20		16,400,000.00
Net cash paid for acquisition of subsidiaries and other business units	21		
Cash paid for other investing activities	22		1,000.00
Sub-total of cash outflows from investing activities	23	28,295.00	16,459,079.00
Net cash flows generated from investing activities	24	22,736,631.40	-1,405,879.00
III. Cash flows generated from financing activities:	25		
Cash received from investments	26		
Cash received from borrowings	27		
Cash received from other financing activities	28		
Sub-total of cash inflows from financing activities	29		
Cash paid for repayment of debts	30		
Cash paid for distribution of dividends, profits or payment of interests	31	9,274,979.80	3,900,000.00
Cash paid for other financing activities	32	799,097.34	761,045.07
Sub-total of cash outflows from financing activities	33	10,074,077.14	4,661,045.07
Net cash flows generated from financing activities	34	-10,074,077.14	-4,661,045.07
IV. Effects of changes in exchange rates on cash and cash equivalents	35		
V. Net increase in cash and cash equivalents	36	34,663,561.99	-118,732,453.78
Add: Balance of cash and cash equivalents as at the beginning of the period	37	436,485,960.79	205,238,782.95
VI. Balance of cash and cash equivalents as at the end of the period	38	471,149,522.78	86,506,329.17

Person in charge of the Company:

Person in charge of accounting:

Head of the accounting department: